ChemicalBook > Product Catalog >Analytical Chemistry >Standard >Pharmaceutical Impurity Reference Standards >(2R,3R,4R,5S)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-fluoro-4-Methyltetrahydrofuran-3-yl benzoate

(2R,3R,4R,5S)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-fluoro-4-Methyltetrahydrofuran-3-yl benzoate

(2R,3R,4R,5S)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-fluoro-4-Methyltetrahydrofuran-3-yl benzoate Structure
CAS No.
874638-94-5
Chemical Name:
(2R,3R,4R,5S)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-fluoro-4-Methyltetrahydrofuran-3-yl benzoate
Synonyms
Sofosbuvir imp-6;Sofosbuvir Impurity X;2'-epi-Sofosbuvir Desphosphate;Sofosbuvir Dibenzoyl Amino Impurity;(2R,3R,4R,5S)-5-(4-Benzamido-2-oxopyrimidin-1(2H)-yl)-2-((be...;(2R,3R,4R,5S)-5-(4-Benzamido-2-oxopyrimidin-1(2H)-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate;Benzamide, N-[1-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]-;N-[1-[(2R)-3,5-Di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-alpha-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]benzamide;Sofosbuvir impurity 21/(2R,3R,4R,5S)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-fluoro-4-Methyltetrahydrofuran-3-yl benzoate
CBNumber:
CB72705027
Molecular Formula:
C31H26FN3O7
Molecular Weight:
571.56
MOL File:
874638-94-5.mol
MSDS File:
SDS

(2R,3R,4R,5S)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-fluoro-4-Methyltetrahydrofuran-3-yl benzoate Properties

Melting point 174-175 °C(Solv: dichloromethane (75-09-2); hexane (110-54-3))
Density 1.34±0.1 g/cm3(Predicted)
pka 8.51±0.20(Predicted)

(2R,3R,4R,5S)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-fluoro-4-Methyltetrahydrofuran-3-yl benzoate Chemical Properties,Uses,Production

Uses

2’-epi-Sofosbuvir Desphosphate is possible metabolite of Sofosbuvir (P839640) which is a prodrug that is metabolized to the active antiviral agent 2''-deoxy-2''-α-fluoro-β-C-methyluridine-5''-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C.

(2R,3R,4R,5S)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-fluoro-4-Methyltetrahydrofuran-3-yl benzoate Preparation Products And Raw materials

Raw materials

Preparation Products

N-[1-[(2R)-3,5-Di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-alpha-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]benzamide 2'-epi-Sofosbuvir Desphosphate Sofosbuvir Impurity X Sofosbuvir impurity 21/(2R,3R,4R,5S)-5-(4-benzaMido-2-oxopyriMidin-1(2H)-yl)-2-((benzoyloxy)Methyl)-4-fluoro-4-Methyltetrahydrofuran-3-yl benzoate Sofosbuvir imp-6 Benzamide, N-[1-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- Sofosbuvir Dibenzoyl Amino Impurity (2R,3R,4R,5S)-5-(4-Benzamido-2-oxopyrimidin-1(2H)-yl)-2-((be... (2R,3R,4R,5S)-5-(4-Benzamido-2-oxopyrimidin-1(2H)-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate 874638-94-5